Stockscreener 앱 받기
40.26
3.34%
1.30
전일 마감가:
$38.96
열려 있는:
$38.17
하루 거래량:
881.83K
Relative Volume:
0.48
시가총액:
$8.27B
수익:
-
순이익/손실:
$-505.61M
주가수익비율:
-14.54
EPS:
-2.7697
순현금흐름:
$-407.32M
1주 성능:
+1.39%
1개월 성능:
+15.99%
6개월 성능:
+53.25%
1년 성능:
+120.24%
1일 변동 폭
$38.01
$40.47
1주일 범위
$37.53
$40.47
52주 변동 폭
$14.32
$41.23
Immunovant Inc Stock (IMVT) Company Profile
명칭
Immunovant Inc
전화
917-410-3120
주소
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
40.26 | 8.00B | 0 | -505.61M | -407.32M | -2.7697 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-20 | 개시 | Bernstein | Mkt Perform |
| 2026-01-06 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | 개시 | Truist | Hold |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-03-03 | 개시 | Jefferies | Hold |
| 2025-01-03 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-09 | 재확인 | Oppenheimer | Outperform |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2024-03-13 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | JP Morgan | Overweight |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-13 | 업그레이드 | UBS | Neutral → Buy |
| 2023-09-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 개시 | BofA Securities | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-31 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2023-02-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2021-08-03 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-01 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-12 | 개시 | Guggenheim | Buy |
| 2020-10-08 | 개시 | Stifel | Buy |
| 2020-10-02 | 개시 | Credit Suisse | Outperform |
| 2020-08-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-07-29 | 개시 | H.C. Wainwright | Buy |
| 2020-02-24 | 개시 | SVB Leerink | Outperform |
모두보기
Immunovant Inc 주식(IMVT)의 최신 뉴스
Immunovant chief legal officer Van Tuyl sells $47,702 in stock By Investing.com - Investing.com India
Immunovant CTO Jay Stout sells $137,924 in IMVT stock - Investing.com
Immunovant CTO Jay Stout sells $137,924 in IMVT stock By Investing.com - Investing.com South Africa
Form 4 Immunovant Inc For: 10 July By Investing.com - Investing.com Nigeria
Immunovant chief legal officer Van Tuyl sells $47,702 in stock - Investing.com
Immunovant COO Melanie Gloria sells $80,531 in shares By Investing.com - Investing.com South Africa
Immunovant COO Melanie Gloria sells $80,531 in shares - Investing.com
Immunovant (IMVT) COO offloads 2,036 shares to cover RSU tax withholding - Stock Titan
Immunovant (IMVT) legal chief sells 1,206 shares in tax “sell to cover” - Stock Titan
Immunovant (IMVT) CTO offloads 3,487 shares in mandated RSU tax-withholding sales - Stock Titan
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $53 - Moomoo
Emerging Therapies Transforming the Myasthenia Gravis Market by DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Roche, Janssen R&D, Immunovant Sciences GmbH, Argenx-Halozyme - Barchart.com
Immunovant Inc explores long term growth paths as autoimmune pipeline advances - ad-hoc-news.de
Understanding Momentum Shifts in (IMVT) - Stock Traders Daily
Immunovant stock hits 52-week high at 39.28 USD By Investing.com - Investing.com South Africa
Immunovant stock hits 52-week high at 39.28 USD - Investing.com
Immunovant Inc outlines its autoimmune drug pipeline as investors watch clinical milestones - ad-hoc-news.de
Form 4 Immunovant Inc For: 6 July By Investing.com - Investing.com Nigeria
Immunovant CEO Eric Venker sells $118,980 of IMVT stock - Investing.com UK
Immunovant CEO Eric Venker sells $118,980 of IMVT stock By Investing.com - Investing.com Nigeria
Immunovant (IMVT) CEO settles CVARs with small tax-related share sale - Stock Titan
All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy - MSN
IMVTImmunovant Inc Earnings - Finviz
Chief Technology Officer Of Immunovant Sold 53% Of Their Shares - Sahm
Immunovant (IMVT) up 3.6% since last earnings report: Can it continue? - MSN
IMVT Maintained by Citigroup -- Price Target Raised to $61.00 - GuruFocus
Immunovant Insider Sold Shares Worth $1,532,309, According to a Recent SEC Filing - Moomoo
Citi Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $61 - Moomoo
Immunovant COO Melanie Gloria sells $678k in company stock By Investing.com - Investing.com India
Immunovant CFO Tiago Girao sells $384,600 in company stock By Investing.com - Investing.com Nigeria
Form 144 IMMUNOVANT For: 26 June By Investing.com - Investing.com South Africa
Immunovant chief legal officer sells $682,886 in stock By Investing.com - Investing.com Nigeria
Insider Sell: Melanie Gloria Sells 17,714 Shares of Immunovant I - GuruFocus
Form 4 Immunovant Inc For: 26 June By Investing.com - Investing.com Nigeria
Avoiding Lag: Real-Time Signals in (IMVT) Movement - Stock Traders Daily
Immunovant CTO Jay Stout sells $1.53m in company stock By Investing.com - Investing.com Australia
Immunovant chief legal officer sells $682,886 in stock - Investing.com
Immunovant (IMVT) CFO exercises options, sells 10,000 shares at ~$38 average - Stock Titan
Immunovant Inc (IMVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Immunovant Inc 주식 (IMVT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Van Tuyl Christopher | Chief Legal Officer |
Jul 08 '26 |
Sale |
39.55 |
1,206 |
47,702 |
179,391 |
| Stout Jay S | Chief Technology Officer |
Jul 08 '26 |
Sale |
39.55 |
3,487 |
137,925 |
208,198 |
| Venker Eric | Chief Executive Officer |
Jul 01 '26 |
Option Exercise |
14.46 |
92,188 |
1,333,038 |
344,001 |
| Venker Eric | Chief Executive Officer |
Jul 02 '26 |
Sale |
38.48 |
3,092 |
118,980 |
254,280 |
| Gloria Melanie | Chief Operating Officer |
Jun 26 '26 |
Sale |
38.31 |
17,714 |
678,604 |
224,393 |
| Stout Jay S | Chief Technology Officer |
Jun 26 '26 |
Sale |
38.31 |
40,000 |
1,532,309 |
211,685 |
| Van Tuyl Christopher | Chief Legal Officer |
Jun 26 '26 |
Option Exercise |
15.20 |
17,824 |
270,925 |
198,421 |
| Van Tuyl Christopher | Chief Legal Officer |
Jun 26 '26 |
Sale |
38.31 |
17,824 |
682,887 |
180,597 |
| Girao Tiago | Chief Financial Officer |
Jun 26 '26 |
Option Exercise |
15.90 |
10,000 |
159,000 |
257,596 |
| Girao Tiago | Chief Financial Officer |
Jun 26 '26 |
Sale |
38.46 |
10,000 |
384,600 |
247,596 |
0.80%
2.11%
자본화:
|
볼륨(24시간):